https://www.selleckchem.com/pr....oducts/bay-1161909.h
The effect of aPCC and rFVIIa was assessed by thrombin generation assay and thromboelastometry. Six people with HA were included. The response to aPCC in thrombin generation after starting emicizumab was significantly stronger than before. This synergistic effect was less pronounced for emicizumab and rFVIIa. Furthermore, aPCC shortened thromboelastometry clotting time more effectively after starting emicizumab than before starting this treatment. We demonstrated a strong synergistic effect of emicizumab and aPCC and a similar but l
Like
Comment
Share
